
Articles
-
6 days ago |
finimize.com | Russell Burns
Let us guess: you’ve been on high alert lately. No wonder: the last six months have featured trade wars, real wars in Ukraine and the Middle East, and a very public spat between the richest and most powerful people in the world, Elon Musk and the US president. That’s a lot for you (and your portfolio) to handle. At the same time, America’s erratic and unpredictable policies have shaken confidence in the US dollar, sending it down around 9% against a basket of currencies this year.
-
1 week ago |
finimize.com | Russell Burns
1 day ago • 2 minsGet smarter in 3 minutes a dayJoin the newsletter that everyone in finance secretly reads. 1M+ subscribers, 100% free. What’s going on here? SoftBank’s looking to build a $1 trillion AI and robotics hub in the Arizona desert – and it wants TSMC and other firms to throw in some green. What does this mean? The ambitious plan (dubbed “Project Crystal Land”) would create a sprawling, China-style industrial complex, but in America.
-
1 week ago |
finimize.com | Russell Burns
The first half of this year has been out of the ordinary, to say the least. After more than a decade of US market dominance, international stocks have charged ahead in the past six months to lead – and not by just a little. That’s had folks wondering whether this is merely a pause in US exceptionalism, or the start of something more permanent. And JPMorgan Private Bank’s just-released outlook for the rest of 2025 could help answer that burning question.
-
1 week ago |
finimize.com | Russell Burns
What’s going on here? Cancel your vacation plans, France: Netflix and TF1 signed a landmark deal, so you can spend next summer watching live sports and soaps on the streaming service. What does this mean? Thanks to streaming services like Netflix, folk can binge a whole series in one night… rather than counting down to 9pm every Wednesday for a measly 45 minutes of content. 📺 That’s stealing eyeballs from traditional TV.
-
1 week ago |
finimize.com | Russell Burns
8 days ago • 15 minsNovo Nordisk has been helping millions of people shed pounds – and putting on serious weight itself. Thanks to its wildly popular GLP-1 medicines for diabetes and obesity, the Danish pharma firm has become one of Europe’s biggest companies, with its shares rising at one point to nearly an 800% gain over just eight years. Now, that sounds like a sweet recipe, but lately, investors have put themselves on a bit of a Novo diet.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →